LFCR Q3 2023 Earnings — Lifecore Biomedical, Inc. Revenue & Financial Results | Market Cap Arena

LFCRLifecore Biomedical, Inc.

$267M

Q3 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$27M-29.0% YoY

Gross Profit

$9M32.2% margin

Operating Income

-$7M-24.6% margin

Net Income

-$37M-137.6% margin

EPS (Diluted)

$-1.20

QoQ Revenue Growth

+21.4%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$22M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$236M

Total Liabilities

$202M

Stockholders' Equity

$34M

Cash & Equivalents

$3M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$27M	$37M	-29.0%
Gross Profit	$9M	$13M	-33.6%
Operating Income	-$7M	-$9M	+23.8%
Net Income	-$37M	-$13M	-179.0%

Geographic Segments

SWITZERLAND

$7M64%

AUSTRALIA

$1M10%

IRELAND

$1M10%

CANADA

$700,0007%

CZECHIA

$700,0007%

All Other Countries

$200,0002%